LEMTRADA, generically known as alemtuzumab, is a prescription medication primarily used in the treatment of relapsing forms of multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system. It is designed to target CD52, a protein found on the surface of immune cells, leading to the depletion of these cells and thereby modifying the course of the disease. LEMTRADA is administered through intravenous infusion, typically in two treatment courses spaced one year apart. Due to its potent immune-modulating effects and the risk of serious side effects, including autoimmune conditions, infusion reactions, and increased risk of infections, LEMTRADA is generally recommended for patients who have had an inadequate response to two or more MS therapies. Its use requires careful patient selection and adherence to a comprehensive monitoring program to manage potential risks and side effects.